ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenue
883
883
614
486
316
216
Revenue Growth (YoY)
18%
44%
26%
54%
46%
4%
Cost of Revenue
341
341
250
181
138
100
Gross Profit
542
542
364
305
177
115
Selling, General & Admin
316
315
237
161
124
84
Research & Development
51
51
44
34
22
11
Operating Expenses
428
427
348
257
207
143
Other Non Operating Income (Expenses)
1
1
-4
0
0
-4
Pretax Income
95
95
-22
19
-62
-56
Income Tax Expense
17
17
-3
1
-14
-13
Net Income
70
70
-20
15
-49
-42
Net Income Growth
-2,433%
-450%
-233%
-131%
17%
91%
Shares Outstanding (Diluted)
22.17
21.22
19.31
18.19
16.3
12.6
Shares Change (YoY)
14%
10%
6%
12%
28.99%
5%
EPS (Diluted)
3.16
3.32
-1.04
0.85
-3.05
-3.4
EPS Growth
-1,723%
-419%
-222%
-128%
-10%
81%
Free Cash Flow
171
171
47
110
-40
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
61.38%
61.38%
59.28%
62.75%
56.01%
53.24%
Operating Margin
12.79%
12.91%
2.44%
9.87%
-9.17%
-12.5%
Profit Margin
7.92%
7.92%
-3.25%
3.08%
-15.5%
-19.44%
Free Cash Flow Margin
19.36%
19.36%
7.65%
22.63%
-12.65%
0%
EBITDA
204
205
82
107
30
20
EBITDA Margin
23.1%
23.21%
13.35%
22.01%
9.49%
9.25%
D&A For EBITDA
91
91
67
59
59
47
EBIT
113
114
15
48
-29
-27
EBIT Margin
12.79%
12.91%
2.44%
9.87%
-9.17%
-12.5%
Effective Tax Rate
17.89%
17.89%
13.63%
5.26%
22.58%
23.21%
Follow-Up Questions
What are ANI Pharmaceuticals Inc's key financial statements?
According to the latest financial statement (Form-10K), ANI Pharmaceuticals Inc has a total asset of $1,440, Net profit of $70
What are the key financial ratios for ANIP?
ANI Pharmaceuticals Inc's Current ratio is 1.6, has a Net margin is 7.92, sales per share of $41.59.
How is ANI Pharmaceuticals Inc's revenue broken down by segment or geography?
ANI Pharmaceuticals Inc largest revenue segment is Generics and Other, at a revenue of 320,034,000 in the most earnings release.For geography, United States is the primary market for ANI Pharmaceuticals Inc, at a revenue of 604,989,000.
Is ANI Pharmaceuticals Inc profitable?
yes, according to the latest financial statements, ANI Pharmaceuticals Inc has a net profit of $70
Does ANI Pharmaceuticals Inc have any liabilities?
yes, ANI Pharmaceuticals Inc has liability of 899
How many outstanding shares for ANI Pharmaceuticals Inc?
ANI Pharmaceuticals Inc has a total outstanding shares of 22.5